- Home
- ANL vs BNTC Comparison
ANL vs BNTC Comparison
Compare ANL & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANL
- BNTC
- Stock Information
- Founded
- ANL 2004
- BNTC 1995
- Country
- ANL Cayman Islands
- BNTC United States
- Employees
- ANL N/A
- BNTC N/A
- Industry
- ANL
- BNTC Biotechnology: Pharmaceutical Preparations
- Sector
- ANL
- BNTC Health Care
- Exchange
- ANL Nasdaq
- BNTC Nasdaq
- Market Cap
- ANL 79.0M
- BNTC 88.1M
- IPO Year
- ANL 2023
- BNTC N/A
- Fundamental
- Price
- ANL $2.05
- BNTC $10.30
- Analyst Decision
- ANL Strong Buy
- BNTC Buy
- Analyst Count
- ANL 2
- BNTC 6
- Target Price
- ANL $9.00
- BNTC $23.83
- AVG Volume (30 Days)
- ANL 13.8K
- BNTC 82.8K
- Earning Date
- ANL 02-24-2025
- BNTC 02-11-2025
- Dividend Yield
- ANL N/A
- BNTC N/A
- EPS Growth
- ANL N/A
- BNTC N/A
- EPS
- ANL N/A
- BNTC N/A
- Revenue
- ANL $5,000,000.00
- BNTC N/A
- Revenue This Year
- ANL N/A
- BNTC N/A
- Revenue Next Year
- ANL N/A
- BNTC N/A
- P/E Ratio
- ANL N/A
- BNTC N/A
- Revenue Growth
- ANL N/A
- BNTC N/A
- 52 Week Low
- ANL $1.85
- BNTC $2.70
- 52 Week High
- ANL $17.48
- BNTC $13.29
- Technical
- Relative Strength Index (RSI)
- ANL 44.92
- BNTC 41.00
- Support Level
- ANL $2.00
- BNTC $10.20
- Resistance Level
- ANL $2.19
- BNTC $11.39
- Average True Range (ATR)
- ANL 0.27
- BNTC 0.87
- MACD
- ANL -0.01
- BNTC -0.19
- Stochastic Oscillator
- ANL 16.81
- BNTC 3.58
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.